Although UHRF1 inhibitor has not been commercially developed, the drug resistance of PCa to abiraterone may be reversed by inducing UHRF1 protein degradation with AKT inhibitor MK2206. This evidence concerns the gene AKT1 and posterior cortical atrophy.